BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Blogs » BioWorld MedTech Perspectives » Not just business as usual for med-tech

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Not just business as usual for med-tech

Oct. 9, 2013
By Omar Ford

images

Medical companies that are still entertaining the notion that business can continue as usual – that somehow the model of collaboration between firms and physicians is enough to foster innovation – are in for a rude awakening.

We live in the “mobile information age,” where customers patients aren’t tethered to bulky computers or laptops to do the necessary research on a treatment method that might be suitable for them. All they need to do is need pull out their smart phone or tablet and at the touch of an ap, they have about 75% of the information they have on their respective disease state.

Patients are becoming smarter and well informed about their treatment options well before they even hit the doctor’s office. So the original method of med-tech firms working along with physicians to best discover valid results in the treatment of care… those are long gone… at least to those who want to succeed and take a leadership position in the space.

On Monday, I spoke with representatives from PricewaterhouseCoopers. The nature of the conversation was PwC’s Health Research Institute report that says that med-tech companies need to stop relying on traditional methods and start thinking more outside the box, when it comes to fostering innovation.

The report specifically states that the “innovation machine is not working like it used to. Today adding nifty features to existing products is not enough to warrant a price increase. Customers — be they hospitals, accountable care organizations (ACOs), or even individual consumers — now demand more in financial, convenience, and health terms. Med-tech companies must focus more on service and business model innovations that meet new industry demands rather than on incremental product improvements. If they don’t, the report says that they risk fierce threats from new players eager to claim a part of this $349 billion global market.

The report is spot on. More and more companies that we interview at Medical Device Daily seem to talk about the customer patient and the involvement that particular customer patient has in using the device. Six years ago, when I started this was something that was barely discussed.

The med-tech companies who will be successful in this endeavor are looking for ways to empower the customer patient and are tailoring solutions that will fit his or her individual needs.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing